Breaking News


Patients with moderate-severe psoriasis regain clinical response during etanercept retreatment


A post-hoc analysis of 226 patients with moderate-severe psoriasis from a 54-week randomized outpatient open-label multicenter trial of etanercept was conducted. Patients had received etanercept 50 mg/2 weeks s.c. until they had received a Physician's Global Assessment (PGA) score of 2 or less. Treatment was then paused until relapse occurred and etanercept was restarted at 25 mg twice weekly. The number of patients with a PGA score of 2 or less on first retreatment were then assessed. It was found that 83% of patients achieved this target and 97% reported satisfaction with etanercept. No new safety concerns emerged and the most common adverse events were upper respiratory tract infections (19%) ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list